Rodrigo Vieira Gomes1, Michele Ângela Rodrigues2, João Bernardo Sancio Rocha Rodrigues1, Paula Teixeira Vidigal3, Karine Araújo Damasceno2, Henrique Araújo Lima1, Dawidson Assis Gomes4, Carla Jorge Machado5, Vivian Resende1. 1. - Faculty of Medicine, Surgery Department, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. 2. - Institute of Biological Sciences, General Pathology, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. 3. - Faculty of Medicine, Pathological Anatomy and Legal Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. 4. - Institute of Biological Sciences, Biochemistry and Immunology, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. 5. - Faculty of Medicine, Preventive and Social Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.
Abstract
OBJECTIVE: to evaluate the expression of the epithelial growth factor receptor (EGFR) by immunohistochemistry, and to verify its association with prognostic factors and survival of patients operated by cholangiocarcinoma. METHODS: we verified the immunohistochemical expression of EGFR in 35 surgical specimens of cholangiocarcinoma (CCA). We obtained survival curves with the Kaplan-Meier method. RESULTS: we found significant EGFR expression in ten (28.6%) of the 35 CCAs, eight with score 3 and two with score 2. Advanced stages (III and IV) presented higher EGFR expression (p=0.07). The clinical characteristics that were most associated with positive EGFR expression were female gender (p=0.06) and absence of comorbidities (p=0.06). Overall survival at 12, 24, 36 and 48 months was 100%, 82.5%, 59% and 44.2%, respectively. The survival of EGFR positive patients at 12, 24, 36 and 48 months was 100%, 75%, 50% and 0%, whereas for negative EGFR patients it was 100%, 87.5%, 65.6% and 65.6%, respectively. CONCLUSION: EGFR expression occurred in 28.6% of the cases studied and was associated with lower survival.
OBJECTIVE: to evaluate the expression of the epithelial growth factor receptor (EGFR) by immunohistochemistry, and to verify its association with prognostic factors and survival of patients operated by cholangiocarcinoma. METHODS: we verified the immunohistochemical expression of EGFR in 35 surgical specimens of cholangiocarcinoma (CCA). We obtained survival curves with the Kaplan-Meier method. RESULTS: we found significant EGFR expression in ten (28.6%) of the 35 CCAs, eight with score 3 and two with score 2. Advanced stages (III and IV) presented higher EGFR expression (p=0.07). The clinical characteristics that were most associated with positive EGFR expression were female gender (p=0.06) and absence of comorbidities (p=0.06). Overall survival at 12, 24, 36 and 48 months was 100%, 82.5%, 59% and 44.2%, respectively. The survival of EGFR positive patients at 12, 24, 36 and 48 months was 100%, 75%, 50% and 0%, whereas for negative EGFRpatients it was 100%, 87.5%, 65.6% and 65.6%, respectively. CONCLUSION:EGFR expression occurred in 28.6% of the cases studied and was associated with lower survival.
Authors: Nádia Marielly Gomes Batista; Antonia Taiane Lopes de Moraes; Karolyny Martins Balbinot; Osvaldo Rodrigues de Souza Neto; Juliana Melo da Silva Brandão; Maria Sueli da Silva Kataoka; Sérgio de Melo Alves Júnior; João de Jesus Viana Pinheiro Journal: BMC Oral Health Date: 2021-03-06 Impact factor: 2.757